Business
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions. With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, supporting fast,
About this update from Alk-abello A/s Class B
[{"type":"image","alt":"ALK Abello","displaySize":"","headline":null,"caption":"ALK Abello","className":"","disableSlideshowImg":false,"size":{"original":{"width":142,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfL7lNIX7z950ZiB3KRYoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a84b59e43cd2eb1b97add5c2b0dfe2b1","width":142,"height":39}},"lazy":false},{"type":"text","content":"ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.","length":373,"tagName":"p"},{"type":"text","content":"With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, supporting fast, reliable emergency treatment and ultimately helping improve the chances of successful outcomes and save lives. EURneffy® offers a longer shelf life (30 months) and superior temperature stability compared to existing adrenaline auto-injectors (AAIs).","length":385,"tagName":"p"},{"type":"text","content":"ALK's Senior Vice President of Commercial Operations in Europe, Flora Beiche-Scholz, said: "Physicians in Germany can now – as the first physicians in Europe – prescribe EURneffy® as an easy-to-bring, user-friendly adrenaline treatment option for patients with life-threatening allergies. With EURneffy®, we aspire to improve the lives of people with severe allergic reactions and facilitate that patients and caregivers consistently carry emergency medication."","length":483,"tagName":"p"},{"type":"text","content":"The EU approval was based on the review of data from the EURneffy® development programme involving more than 700 participants. No serious adverse events were reported in clinical studies with EURneffy®. The extensive clinical pharmacological data of EURneffy® 2 mg was comparable to AAIs, with the pharmacodynamics and pharmacokinetics evaluated across a range of dosing conditions. EURneffy® with a 1 mg dosage for patients weighing 15-30 kg is c...